GMAB
Genmab A/S
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
News
No thesis.
Genmab A/S
57.15
No implied move.
No implied move.
Expected move
No implied move.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Paradigm Biocapital AdvisorsParadigm Biocapital | $360.8M | 12.28% | +64.83% | |
| 2 | Orbis Allan GrayOrbis Allan Gray | $312.3M | 10.63% | −12.05% | |
| 3 | Deep Track CapitalDeep Track Capital | $237.6M | 8.09% | +136.13% | |
| 4 | AlliancebernsteinAlliancebernstein | $231.9M | 7.89% | −9.55% | |
| 5 | Deerfield ManagementDeerfield | $188.6M | 6.42% | +178.84% | |
| 6 | Arrowstreet Capital, Limited PartnershipArrowstreet Capital, Limited Partnership | $136.7M | 4.65% | 0.00% | |
| 7 | BlackRockBlackRockindex-like | $128.3M | 4.37% | +2.97% | |
| 8 | Sofinnova InvestmentsSofinnova | $111.1M | 3.78% | +437.74% | |
| 9 | Renaissance TechnologiesRenaissance Technologies | $96.6M | 3.29% | −20.31% | |
| 10 | Two Sigma InvestmentsTwo Sigma | $96.3M | 3.28% | +49.90% | |
| 11 | Harding LoevnerHarding Loevner | $86.9M | 2.96% | −4.50% | |
| 12 | Citadel AdvisorsCitadel | $77.8M | 2.65% | +1542.66% | |
| 13 | First Trust AdvisorsFirst Trust | $75.7M | 2.58% | +11.99% | |
| 14 | Qube Research & TechnologiesQube Research & Technologies | $46.4M | 1.58% | +149.40% | |
| 15 | Morgan StanleyMorgan Stanley | $44.8M | 1.52% | −25.38% | |
| 16 | Federated InvestorsFederated Investors | $39.8M | 1.36% | +15.80% | |
| 17 | Goldman Sachs GroupGoldman Sachs | $35.1M | 1.20% | +37.37% | |
| 18 | Franklin ResourcesFranklin Resources | $33.0M | 1.12% | +0.82% | |
| 19 | Pictet Asset Management HoldingPictet | $29.3M | 1.00% | −1.07% | |
| 20 | UBS GroupUBS | $26.4M | 0.90% | +222.36% | |
| 21 | PerpetualPerpetual | $25.2M | 0.86% | +21.17% | |
| 22 | Northern TrustNorthern Trustindex-like | $25.2M | 0.86% | −3.57% | |
| 23 | Millennium ManagementMillennium | $25.0M | 0.85% | +14.93% | |
| 24 | Caption ManagementCaption | $24.7M | 0.84% | new | |
| 25 | Russell Investments GroupRussell | $24.3M | 0.83% | +10.83% |
292 managers report $2.9B of Genmab A/S on form 13F for the quarter ended Jun 30 '26. 19 of them hold 80% of it; Paradigm Biocapital is largest at 12.28%.